Sandoz Will Consider Local Partnerships In China
As it builds a portfolio in the Chinese market, which is increasingly focused on high-quality products, Sandoz is considering teaming up with local players for certain drugs.
You may also be interested in...
Sandoz says a first-of-its-kind Chinese approval for generic rosuvastatin will open the door for the firm to participate in local tenders.
In line with its strategy to expand its biosimilars business, Sandoz has entered into an agreement with China’s Gan & Lee to market and supply three insulin biosimilars in the EU, US, and other key territories.
As China’s government raises quality standards for generics, Sandoz views the local market as promising, according to the Novartis division’s head, Richard Francis.